TRCT
LAB icon

Tower Research Capital (TRC)’s Standard BioTools LAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.3K Buy
34,098
+24,805
+267% +$30K ﹤0.01% 3133
2025
Q4 		$11.9K Sell
9,293
-16,161
-63% -$21.7K ﹤0.01% 3538
2025
Q3 		$33.1K Sell
25,454
-11,207
-31% -$14.7K ﹤0.01% 2861
2025
Q2 		$44K Sell
36,661
-4,271
-10% -$4.73K ﹤0.01% 3082
2025
Q1 		$44.2K Buy
40,932
+38,803
+1,823% +$54.5K ﹤0.01% 2310
2024
Q4 		$3.73K Sell
2,129
-1,841
-46% -$3.43K ﹤0.01% 4603
2024
Q3 		$7.66K Buy
+3,970
New +$7.77K ﹤0.01% 4031
2024
Q2 		– Sell
-26,803
Closed -$72.6K – 5869
2024
Q1 		$72.6K Buy
26,803
+17,486
+188% +$42.2K ﹤0.01% 2023
2023
Q4 		$20.6K Buy
9,317
+2,893
+45% +$6.17K ﹤0.01% 3630
2023
Q3 		$18.6K Buy
6,424
+485
+8% +$1.27K ﹤0.01% 3439
2023
Q2 		$11.5K Sell
5,939
-295
-5% -$582 ﹤0.01% 3972
2023
Q1 		$12K Sell
6,234
-17,289
-73% -$34.2K ﹤0.01% 4091
2022
Q4 		$28K Buy
+23,523
New +$29K ﹤0.01% 2812
2022
Q3 		– Sell
-5,967
Closed -$10K – 6303
2022
Q2 		$10K Sell
5,967
-5,856
-50% -$14.5K ﹤0.01% 4459
2022
Q1 		$42K Sell
11,823
-26,900
-69% -$92.9K ﹤0.01% 2872
2021
Q4 		$152K Buy
38,723
+25,928
+203% +$121K ﹤0.01% 1966
2021
Q3 		$84K Buy
12,795
+7,648
+149% +$50.3K ﹤0.01% 2536
2021
Q2 		$32K Sell
5,147
-34,583
-87% -$185K ﹤0.01% 3422
2021
Q1 		$180K Buy
39,730
+28,802
+264% +$158K ﹤0.01% 2102
2020
Q4 		$65K Sell
10,928
-66,283
-86% -$435K ﹤0.01% 2820
2020
Q3 		$574K Buy
77,211
+56,767
+278% +$392K 0.01% 1533
2020
Q2 		$82K Buy
+20,444
New +$71.2K ﹤0.01% 2636
2019
Q4 		– Sell
-6,135
Closed -$29K – 3983
2019
Q3 		$29K Buy
6,135
+6,106
+21,055% +$48.1K ﹤0.01% 2212
2019
Q2 		$0 Buy
+29
New +$369 ﹤0.01% 3995
2019
Q1 		– Sell
-538
Closed -$5K – 4058
2018
Q4 		$5K Sell
538
-4,535
-89% -$35.3K ﹤0.01% 2912
2018
Q3 		$38K Buy
5,073
+940
+23% +$6.68K ﹤0.01% 1932
2018
Q2 		$25K Sell
4,133
-12,817
-76% -$73K ﹤0.01% 2298
2018
Q1 		$99K Buy
16,950
+7,133
+73% +$46.8K 0.01% 1266
2017
Q4 		$58K Sell
9,817
-1,822
-16% -$9.97K 0.01% 1226
2017
Q3 		$59K Buy
+11,639
New +$48.9K ﹤0.01% 1818
2017
Q1 		– Sell
-173
Closed -$1K – 3519
2016
Q4 		$1K Buy
173
+48
+38% +$301 ﹤0.01% 3616
2016
Q3 		$1K Sell
125
-1,056
-89% -$9.7K ﹤0.01% 3319
2016
Q2 		$11K Sell
1,181
-505
-30% -$4.75K ﹤0.01% 2730
2016
Q1 		$14K Buy
+1,686
New +$12.2K ﹤0.01% 1626
2015
Q4 		– Sell
-1,237
Closed -$10K – 4787
2015
Q3 		$10K Buy
1,237
+1,154
+1,390% +$18.2K ﹤0.01% 2313
2015
Q2 		$2K Sell
83
-399
-83% -$12.6K ﹤0.01% 3741
2015
Q1 		$20K Buy
+482
New +$19.1K ﹤0.01% 2244
2014
Q4 		– Sell
-685
Closed -$17K – 4364
2014
Q3 		$17K Buy
685
+275
+67% +$7.73K ﹤0.01% 2432
2014
Q2 		$12K Buy
+410
New +$13.1K ﹤0.01% 2213
2014
Q1 		– Sell
-1,550
Closed -$59K – 4695
2013
Q4 		$59K Sell
1,550
-2,200
-59% -$64.8K 0.01% 1254
2013
Q3 		$82K Buy
+3,750
New +$73.7K 0.01% 1477

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Tower Research Capital (TRC)'s LAB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Standard BioTools (LAB) stake by 267% in Q1 2026, buying an estimated $30K and bringing the position to 34,098 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3133.

Tower Research Capital (TRC) first reported a position in LAB in Q3 2013 and has held it in 41 quarters since. The position peaked at $574K in Q3 2020. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Tower Research Capital (TRC) held 34,098 shares of Standard BioTools worth $31.3K as of Q1 2026.
  • Tower Research Capital (TRC) bought 24,805 Standard BioTools shares in Q1 2026, an estimated $30K.
  • Standard BioTools made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3133 holding.
  • Tower Research Capital (TRC) first reported a position in Standard BioTools in Q3 2013 and has held it in 41 quarters since.
  • Tower Research Capital (TRC)'s Standard BioTools position peaked at $574K in Q3 2020.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.